Register
FDA expands indication of baloxavir use to people at high-risk for flu complications |
Clinical News
eMediNexus Coverage from: 
FDA expands indication of baloxavir use to people at high-risk for flu complications

1 Read Comments                

The US Food and Drug Administration (FDA) has expanded the indication for baloxavir marboxil tablets (Xofluza, Genentech) to include people at high risk of developing influenza-related complications.

The new indication regards patients with conditions such as asthma, chronic lung disease, diabetes, heart disease, or morbid obesity and for adults aged 65 years or older.

Baloxavir marboxil has been approved for the treatment of acute uncomplicated influenza in people aged 12 years or older who have been symptomatic for no more than 48 hours. It is given as a single oral dose.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now